| Rebecca Wiesner, DPM | |
|
1379 Enfield St, Enfield, CT 06082-5524 | |
| (860) 741-3041 | |
| (860) 741-5644 |
| Full Name | Rebecca Wiesner |
|---|---|
| Gender | Female |
| Speciality | Podiatry |
| Experience | 12 Years |
| Location | 1379 Enfield St, Enfield, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104183391 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Podiatrycare P C | 7719022987 | 5 |
News Archive
A new class of cancer drugs can be used effectively while minimizing hypertensive side effects if patients' blood pressure is closely monitored and controlled, a clinical panel has determined.
A national study led by a USC researcher found people who encountered the threat of being judged by negative stereotypes related to weight, age, race, gender, or social class in health care settings reported adverse effects.
Michelle Hastings, PhD, Assistant Professor in the Department of Cell Biology and Anatomy, in the Chicago Medical School of Rosalind Franklin University of Medicine and Science, has been awarded a five-year $1.68 million grant from the National Institutes of Health to support her research aimed at investigating treatments for the fatal children's disease, Spinal Muscular Atrophy (SMA).
BioCryst Pharmaceuticals, Inc. announced positive top-line results from its randomized, double-blind, multi-center, placebo-controlled Phase 2 study designed to evaluate the urate-lowering activity and safety of several doses of BCX4208 alone and in combination with selected doses of allopurinol administered once-daily.
› Verified 1 days ago
| Provider Name | Podiatrycare P C |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1396875365 PECOS PAC ID: 7719022987 Enrollment ID: O20100301000015 |
News Archive
A new class of cancer drugs can be used effectively while minimizing hypertensive side effects if patients' blood pressure is closely monitored and controlled, a clinical panel has determined.
A national study led by a USC researcher found people who encountered the threat of being judged by negative stereotypes related to weight, age, race, gender, or social class in health care settings reported adverse effects.
Michelle Hastings, PhD, Assistant Professor in the Department of Cell Biology and Anatomy, in the Chicago Medical School of Rosalind Franklin University of Medicine and Science, has been awarded a five-year $1.68 million grant from the National Institutes of Health to support her research aimed at investigating treatments for the fatal children's disease, Spinal Muscular Atrophy (SMA).
BioCryst Pharmaceuticals, Inc. announced positive top-line results from its randomized, double-blind, multi-center, placebo-controlled Phase 2 study designed to evaluate the urate-lowering activity and safety of several doses of BCX4208 alone and in combination with selected doses of allopurinol administered once-daily.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Rebecca Wiesner, DPM 1379 Enfield St, Enfield, CT 06082-5524 Ph: (860) 741-3041 | Rebecca Wiesner, DPM 1379 Enfield St, Enfield, CT 06082-5524 Ph: (860) 741-3041 |
News Archive
A new class of cancer drugs can be used effectively while minimizing hypertensive side effects if patients' blood pressure is closely monitored and controlled, a clinical panel has determined.
A national study led by a USC researcher found people who encountered the threat of being judged by negative stereotypes related to weight, age, race, gender, or social class in health care settings reported adverse effects.
Michelle Hastings, PhD, Assistant Professor in the Department of Cell Biology and Anatomy, in the Chicago Medical School of Rosalind Franklin University of Medicine and Science, has been awarded a five-year $1.68 million grant from the National Institutes of Health to support her research aimed at investigating treatments for the fatal children's disease, Spinal Muscular Atrophy (SMA).
BioCryst Pharmaceuticals, Inc. announced positive top-line results from its randomized, double-blind, multi-center, placebo-controlled Phase 2 study designed to evaluate the urate-lowering activity and safety of several doses of BCX4208 alone and in combination with selected doses of allopurinol administered once-daily.
› Verified 1 days ago
Podiatrycare P C Podiatrist Medicare: Medicare Enrolled Practice Location: 1379 Enfield St, Enfield, CT 06082 Phone: 860-741-3041 Fax: 860-741-5644 | |
Charlotte George, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1379 Enfield St, Enfield, CT 06082 Phone: 860-741-3041 Fax: 860-741-5644 | |
Dr. Edwin Steven Damon, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 64 Palomba Dr, Enfield, CT 06082 Phone: 860-745-6248 Fax: 860-741-2482 | |
Laura C Vander Poel, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1379 Enfield Street, Enfield, CT 06082 Phone: 860-741-3041 | |
Kristen E Winters, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1379 Enfield St, Enfield, CT 06082 Phone: 860-741-3041 Fax: 860-741-5644 | |
E Steven Damon, D.p.m. Podiatrist Medicare: Medicare Enrolled Practice Location: 64 Palomba Dr, Enfield, CT 06082 Phone: 860-745-6248 Fax: 860-741-2482 |